India bans 16 fixed-dose drug combinations citing safety and lack of therapeutic justification

Centre Bans 16 Fixed-Dose Combination Drugs, Cites Public Health Risks And Safety Concerns

Mumbai, June 20: In a significant move aimed at strengthening drug safety, the Central government has prohibited the manufacture, sale, distribution and storage of 16 Fixed Dose Combination (FDC) drugs for human use with immediate effect, stating that their use is likely to pose a risk to human health.The banned medicines were being used for a range of conditions, including bacterial infections, pain management, gastrointestinal disorders, diabetes care and dermatological treatments.Expert panel flags safety concernsThe decision follows a review by an expert committee, which concluded that these drug combinations lack therapeutic justification and may pose risks to public health. Acting on the committee's recommendations, the government invoked Section 26A of the Drugs and Cosmetics Act, 1940, which empowers it to prohibit drugs deemed unsafe, ineffective or irrational in the public interest.Fixed Dose Combinations are medicines that contain two or more active pharmaceutical ingredients in a fixed ratio within a single dosage form. While many FDCs help improve patient compliance and reduce pill burden, regulators have increasingly scrutinised combinations that offer no proven therapeutic advantage or expose patients to unnecessary risks.The combinations identified by the expert panel were used across multiple therapeutic areas, including bacterial infections, pain relief, gastrointestinal disorders, diabetes management and skin care. Public health experts have expressed particular concern over certain antibiotic combinations, warning that irrational use of antibiotics can contribute to the growing threat of antimicrobial resistance.Irrational combinations identifiedAmong the prohibited combinations is Gliclazide + Chromium Picolinate, which was marketed for the management of Type 2 diabetes. Another is Dicyclomine + Paracetamol + Clidinium Bromide, which was used to relieve abdominal pain, intestinal spasms and gastrointestinal disorders. The expert panel found that these combinations lacked adequate therapeutic justification and that their risks outweighed any perceived benefits.Experts say medicines without sound scientific evidence may increase the likelihood of adverse drug reactions, complicate treatment decisions and add to healthcare costs without improving patient outcomes. The government's action is part of ongoing efforts to promote rational drug use and ensure that medicines available in the market meet established standards of safety and efficacy.Also Watch: Centre Bans 16 Drug Combinations Over Safety Concerns, Lack Of Therapeutic JustificationImmediate effect of notificationWith the notification coming into force immediately, manufacturers, distributors and retailers have been directed to stop the manufacture, sale, distribution and storage of the affected formulations. The move is expected to further strengthen India's commitment to patient safety and the rational use of medicines.To get details on exclusive and budget-friendly property deals in Mumbai & surrounding regions, do visit: https://budgetproperties.in/

17 hours ago

Centre Bans 16 Drug Combinations Over Safety Concerns, Lack Of Therapeutic Justification

The Centre has banned the manufacture, sale, distribution and supply of 16 fixed-dose combination (FDC) drugs across India, saying the medicines lack therapeutic justification and pose potential risks to patients.The decision was taken by the Union Health Ministry following a scientific review of various drug combinations. In a notification issued under Section 26A of the Drugs and Cosmetics Act, 1940, the ministry said the identified FDCs were not considered beneficial when weighed against the risks involved. The ban has come into effect immediately.Safety over convenienceFixed-dose combination drugs contain two or more active pharmaceutical ingredients in a fixed ratio. While such medicines are commonly used to improve treatment compliance and reduce the number of pills a patient takes, authorities said not all combinations are supported by scientific evidence.The ministry said the move is aimed at safeguarding public health and promoting the rational use of medicines. It added that only medicines that are effective and scientifically validated should remain available to the public. The decision also reflects a stricter regulatory approach towards drug combinations that may offer little additional benefit while exposing patients to unnecessary risks.The action follows a review undertaken in compliance with directions issued by the Supreme Court. As part of the process, the Drugs Technical Advisory Board (DTAB) constituted an expert committee to examine different drug combinations and identify formulations that were irrational, therapeutically unjustified or potentially harmful.Wide range of formulations affectedAmong the combinations prohibited are Acetyl Salicylic Acid with Ethoheptazine; Dicyclomine, Paracetamol and Clidinium Bromide; Dicyclomine, Paracetamol, Clidinium Bromide and Chlordiazepoxide; Gliclazide with Chromium Picolinate; and Paracetamol with Lignocaine.Several antibiotic-based combinations have also been banned. These include Amoxicillin with Serratiopeptidase, Amoxicillin with Serratiopeptidase and Lactobacillus Sporogenes, Amoxicillin with Cloxacillin, Lactic Acid Bacillus and Serratiopeptidase, Cefadroxyl with Probenecid, and Cefuroxime with Serratiopeptidase.The prohibited list also covers a number of dermatological and skincare formulations containing Aloe Vera or Aloe Extract combined with ingredients such as Vitamin E, Jojoba Oil, Orange Oil, Wheat Germ Oil, Tea Tree Oil, Allantoin and D-Panthenol.Push for rational drug useThe ministry noted that the latest action is part of the government's broader effort to strengthen patient safety and encourage the rational use of medicines. It recalled that several irrational FDCs had been prohibited in previous years after detailed scientific reviews.Also Watch: CDSCO Makes Pharmacovigilance Compliance Mandatory For Pharma Companies To Strengthen Drug Safety MonitoringTo ensure compliance, all state drug controllers, regulatory authorities and enforcement agencies have been directed to strictly implement the notifications. Manufacturers, importers, distributors and other stakeholders have also been advised to take the necessary corrective measures in line with the law.(With inputs from agencies)

17 hours ago

Centre Bans 16 Fixed-Dose Combination Drugs After Safety Review, Cites Lack Of Medical Justification

The Government of India has imposed an immediate nationwide ban on 16 fixed-dose combination (FDC) medicines following a detailed scientific review that found the formulations lacked medical justification for continued use. The decision was notified under Section 26A of the Drugs and Cosmetics Act, 1940.In its official announcement, the Union Health Ministry stated that the “manufacture for sale, sale, distribution and supply” of the identified 16 FDCs for human use has been prohibited with immediate effect across the country. The banned drugs span several therapeutic categories, including antibiotics, pain management combinations, antispasmodic drugs, and dermatological formulations.Among the prohibited combinations are drugs such as Acetyl Salicylic Acid with Ethoheptazine; combinations of Dicyclomine, Paracetamol and Clidinium Bromide; and multi-drug formulations including Dicyclomine, Paracetamol, Clidinium Bromide and Chlordiazepoxide. Other restricted products include Gliclazide with Chromium Picolinate and Paracetamol with Lignocaine.The order also targets multiple antibiotic combinations, including Amoxicillin with Serratiopeptidase, Amoxicillin with Cloxacillin, and combinations involving Lactobacillus Sporogenes and Serratiopeptidase. Additionally, Cefadroxyl with Probenecid and Cefuroxime with Serratiopeptidase have been banned.How Supply Chains Constraints Have Made Chemotherapy Drugs Cisplatin And Carboplatin Costlier? Certain dermatological and skincare FDCs containing Aloe Vera or Aloe Extract combined with ingredients like Vitamin E, Jojoba Oil, Tea Tree Oil, and D-Panthenol have also been prohibited.The action follows a comprehensive review of FDC medicines initiated after directions from the Supreme Court. The Drugs Technical Advisory Board formed an expert committee to evaluate existing combinations and identify those deemed irrational, unsafe, or lacking therapeutic value.The ministry clarified that fixed-dose combination drugs contain two or more active ingredients in fixed proportions, but the banned formulations were found to have no adequate therapeutic rationale or benefit compared to associated risks.The government stated that the decision is aimed at safeguarding public health, ensuring rational drug use, and strengthening evidence-based prescribing practices. It also directed state drug regulators and enforcement agencies to implement the ban, while manufacturers and distributors must comply immediately with corrective measures.

20 hours ago

Government bans 16 fixed-dose drug combinations: Here's the list

The Indian government has banned 16 popular drug combinations, deeming them therapeutically unjustified and potentially risky. This decisive action by the Union Health Ministry aims to protect public health and ensure only effective, scientifically validated medicines reach consumers. The prohibited formulations cover pain relief, muscle relaxation, diabetes management, and antibiotic categories, including several widely used antibiotic mixes and certain skincare products.

21 hours ago